Bisphosphonates

ApprovedSmall molecule

VVanderbilt-Ingram Cancer Center

Bisphosphonates is one of 91 small molecule programs targeting Osteogenesis Imperfecta. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteogenesis ImperfectaActive, not recruiting

Adverse EffectActive, not recruiting

OsteoporosisActive, not recruiting

Osteogenesis ImperfectaPreclinical

Active, not recruiting

Adverse EffectPreclinical

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

Competition

Competitive Landscape

172 competitors in Osteoporosis

#DrugCompanyPhaseTrials

One-Alpha

Roche

Phase 3

3 2

Livial

Pfizer

Phase 3

1 3

Depo-Provera

Tymlos

2 5

Bisphosphonates

VVanderbilt-Ingram Cancer Center

Approved

1 6

Oxycodone IR

Johnson & Johnson

Phase 3

1 7

Salmon Calcitonin

Novartis

Phase 3

1 8

Bazedoxifene Acetate

Pfizer

Phase 3

2 9

Arzoxifene

Eli Lilly

Phase 3

2 10

Ibandronic Acid

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Recruiting

Osteogenesis Imperfecta

NCT04115774

Clinical

Trials by Indication[1]

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Women1 trial

Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women

Completed·—··NCT02115490·60 enrolled

Osteoporosis1 trial

Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis

Completed·TTuen Mun Hospital·Phase 4·NCT01465568·40 enrolled

Osteogenesis Imperfecta1 trial

Registry of Osteogenesis Imperfecta

Recruiting·LLuca Sangiorgi··NCT04115774·5,000 enrolled

Adverse Effect1 trial

A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients

Unknown status·SSun Yat-sen University··NCT03543072·2,000 enrolled

2 more indications

Vertebral Compression Fracture1 trial

Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

Withdrawn·UUniversity of California, Davis·Phase 4·NCT03651804

Unspecified1 trial

The Effect of Long-term Use of Bisphosphonates on Femur Morphology

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06621069·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Bisphosphonates. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonates compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonates. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VVanderbilt-Ingram Cancer Center

Bisphosphonates

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Minimal Residual Disease1 trial

Women1 trial

Osteoporosis1 trial

Osteogenesis Imperfecta1 trial

Adverse Effect1 trial

Vertebral Compression Fracture1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News